Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor

Inclusion Criteria:

1. Male or female, age ranging from 18 to 70 years old (excluding 70 years old);
2. body weight ≥45 kg;
3. Histologically or cytologically confirmed diagnosis of malignant solid tumor;
4. Solid tumor patients who receive a 3-week chemotherapy regimen have been evaluated as high-risk for FN or evaluated as having moderate risk for FN, but with an increased risk factor for neutropenia associated with the chemotherapy regimen;(The risk assessment of FN in tumor chemotherapy is based on " Chinese Society of Clinical Oncology (CSCO) guidelines for standardized management of tumor chemoradiotherapy related neutropenia(2021 edition)" and " Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China(2023 edition)";
5. Karnofsky Performance Scale(KPS) score≥70;
6. The total number of white blood cells and absolute value of neutrophils before chemotherapy should not be lower than normal values: WBC ≥ 3.5 × 109/L, ANC ≥ 1.5 × 109/L;
7. Subject has a life Expectation of at least 6 month；
8. Subjects voluntarily and strictly comply with the research protocol requirements and sign a written informed consent for.

Exclusion Criteria:

1. Received any other PEG-rhG-CSF within 4 weeks prior to participating in this study;
2. Patients receiving intermittent or continuous chemotherapy regimens such as albumin paclitaxel and capecitabine;
3. Previously or expected to receive extensive radiation therapy (\>25% of total bone marrow);
4. Individuals with significant functional impairments in important organs such as the heart, lungs, liver, and kidneys:

   Liver function indicators (ALT, TBil)\>2.5 ULN; Tumor patients with liver metastasis have liver function indicators (ALT,TBil)\>5ULN; Hepatitis B virus infection, hepatitis C virus infection, or cirrhosis; Renal function Cr\>1.5ULN;
5. Pregnant or breastfeeding woman ;
6. hypersensitive to rhG-CSF or other biological agents;
7. Investigators judged other situations that may affect the progress and results of clinical research.